What is Alogliptin / Pioglitazone made from?

This combination contains two active ingredients: alogliptin benzoate, a dipeptidyl peptidaseâ4 (DPPâ4) inhibitor, and pioglitazone hydrochloride, a thiazolidinedione that increases insulin sensitivity.

Alogliptin / pioglitazone Tablet bulk supplier for pharma manufacturers

Alogliptin / Pioglitazone Tablet Suppliers & Bulk Manufacturers

Q: What is generic name of Alogliptin / Pioglitazone?

The generic name is alogliptin and pioglitazone.

Q: What is brand name of Alogliptin / Pioglitazone?

Common brand names include Oseni and Incresync.

Available Forms: Tablets

Available Strengths: 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg

Reference Brands: Oseni (USA), Incresync(EU)

Category: Diabetes

Alogliptin/pioglitazone is an oral medication for type 2 diabetes mellitus. It combines alogliptin, a DPP-4 inhibitor, and pioglitazone, a thiazolidinedione, to help control blood sugar levels. The combination improves insulin response and reduces liver glucose production. Taken once daily, it is used when diet, exercise, or single-drug therapy is insufficient.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Alogliptin / Pioglitazone is a fixed-dose combination anti-diabetic medication designed to improve glycemic control in adults with type 2 diabetes mellitus (T2D). Type 2 diabetes is a progressive condition that often requires sequential additions of therapy to maintain blood glucose levels. By combining two complementary mechanisms of action, this combination provides an effective and convenient treatment option. Alogliptin, a dipeptidyl peptidase-4 (DPP‑4) inhibitor, increases incretin activity, enhancing insulin release and suppressing glucagon secretion in a glucose-dependent manner. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in peripheral tissues, helping to lower blood glucose and support long-term glycemic control.

Fixed-dose combinations like Alogliptin / Pioglitazone simplify therapy regimens, which can enhance medication adherence and improve patient outcomes. The combination is marketed globally under brand names such as Oseni and Incresync. Use of this therapy should be guided by individual patient needs, considering factors such as renal function, cardiovascular status, and potential adverse effects. Regular monitoring and collaboration with healthcare professionals ensure safe and effective management of type 2 diabetes with this combination therapy.

Alogliptin / Pioglitazone Tablet — third party manufacturing & bulk supply

Alogliptin / Pioglitazone Tablet is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Alogliptin / Pioglitazone Tablet is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Alogliptin / Pioglitazone Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Alogliptin / Pioglitazone Tablet →

Back to Listing

Frequently Asked Questions

Alogliptin / Pioglitazone is used to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin increases incretin activity to enhance insulin release and suppress glucagon levels, while pioglitazone improves insulin sensitivity in peripheral tissues, helping to lower blood glucose levels when diet and exercise alone are not sufficient.

This combination contains two active ingredients: alogliptin benzoate, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, and pioglitazone hydrochloride, a thiazolidinedione that increases insulin sensitivity.

The combination product is marketed under brand names such as Oseni and Incresync in various regions.

It is manufactured by multiple pharmaceutical companies globally, including generic manufacturers approved in different countries.

The generic name is alogliptin and pioglitazone.

Common brand names include Oseni and Incresync.

Alogliptin / Pioglitazone is manufactured in several countries, including India, the USA, and European nations, by approved pharmaceutical manufacturers.